Business
Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
Conference Call Scheduled for Friday, May 15, 2026, at 1:00 PM ET NEEDHAM, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer, today announced that Candel’s management will host a webcast and conference call on Friday, May 15, 2026 at 1:00 PM ET. The call will discuss the Company’s extended follow-up data f
About this update from Candel Therapeutics, Inc.
[{"type":"image","alt":"Candel Therapeutics","displaySize":"","headline":null,"caption":"Candel Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":137,"url":"https://media.zenfs.com/en/globenewswire.com/e791e10481877ea34bb2d8e55bba5dfe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.UDl8bhJsgxnqpejVYBG6Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5Mg--/https://media.zenfs.com/en/globenewswire.com/e791e10481877ea34bb2d8e55bba5dfe","width":300,"height":137}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Conference Call Scheduled for Friday, May 15, 2026, at 1:00 PM ET","length":65,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":65,"olType":false},{"type":"text","content":"NEEDHAM, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer, today announced that Candel’s management will host a webcast and conference call on Friday, May 15, 2026 at 1:00 PM ET. The call will discuss the Company’s extended follow-up data from the phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with intermediate- to high-risk localized prostate cancer. The discussion will follow the oral plenary presentation of these data by Mark G. Garzatto, M.D., Professor of Urology at Oregon Health & Science University and the Portland VA Medical Center, at the American Urological Association (AUA) 2026 Annual Meeting.","length":853,"tagName":"p"},{"type":"text","content":"The call will feature insights from leading prostate cancer specialists, including; Neal D. Shore, M.D., FACS, START Carolinas/Carolina Urologic Research Center, Head of GU Oncology and Radiopharm, Myrtle Beach, SC, USA; Jonathan D. Tward, M.D., Ph.D., FASTRO, Professor of Radiation Oncology, Huntsman Cancer Institute, University of Utah, and Daniel J. George, M.D., Professor of Medicine, Urology and Surgery, Duke University School of Medicine, Director of Genitourinary Oncology, Duke Cancer Institute.","length":507,"tagName":"p"},{"type":"text","content":"Dr. Shore is a renowned urologic oncologist with a focus on genitourinary oncology. He has led more than 500 clinical trials and authored over 350 peer-review...